Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Protocol: L045M
______________________________________________________________________________

| 509 |H02AB04| METHYLPREDNISOLONUM (5) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB04 METHYLPREDNISOLONUM COMPR. 16 mg

MEDROL A 16 16 mg PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 32 mg

MEDROL 32 32 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM COMPR. 4 mg

MEDROL 4 mg 4 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 510 |L01AA01| CYCLOPHOSPHAMIDUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. 1 g

INJ./PERF.

ENDOXAN(R) 1 g 1 g BAXTER ONCOLOGY GMBH

L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. 200 mg

PERF./INJ. I.V.

ENDOXAN 200 mg 200 mg ACTAVIS S.R.L.
L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. 500 mg

INJ./PERF.

ENDOXAN(R) 500 mg 500 mg BAXTER ONCOLOGY GMBH
L01AA01 CYCLOPHOSPHAMIDUM DRAJ. 50 mg

ENDOXAN(R) 50 mg 50 mg BAXTER ONCOLOGY GMBH

________________________________________________________________________________
______________________________________________________________________________

| 511 |L04AX01| AZATHIOPRINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 512 |P01BA02| HYDROXYCHLOROQUINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

P01BA02 HYDROXYCHLOROQUINUM COMPR. FILM. 200 mg

PLAQUENIL(R) 200 mg SANOFI-SYNTHELABO LTD.

________________________________________________________________________________

SUBLISTA C1 - G18 POLIARTRITA REUMATOIDĂ, ARTROPATIA PSORIAZICĂ ŞI ARTRITA JUVENILĂ.
______________________________________________________________________________

| 513 |A07EC01| SULFASALAZINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A07EC01 SULFASALAZINUM COMPR. FILM. 500 mg

SALAZIDIN 500 mg AC HELCOR SRL
A07EC01 SULFASALAZINUM COMPR. FILM. GASTROREZ. 500 mg

SULFASALAZIN EN 500 mg KRKA D.D. NOVO MESTO

________________________________________________________________________________
______________________________________________________________________________

| 514 |H02AB01| BETAMETHASONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB01 BETAMETHASONUM SUSP. INJ. I.M. 7 mg/ml

DIPROPHOS(R) 7 mg/ml SCHERING PLOUGH EUROPE

________________________________________________________________________________

______________________________________________________________________________

| 515 |H02AB04| METHYLPREDNISOLONUM (5) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB04 METHYLPREDNISOLONUM COMPR. 16 mg

MEDROL A 16 16 mg PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 32 mg

MEDROL 32 32 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM COMPR. 4 mg

MEDROL 4 mg 4 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 516 |L01BA01| METHOTREXATUM (4) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BA01 METHOTREXATUM

________________________________________________________________________________
______________________________________________________________________________

| 517 |L04AA01| CICLOSPORINUM* | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Terapie de menţinere ulterioară iniţierii şi stabilizării tratamentului cu ciclosporina, la pacienţii cu poliartrită reumatoidă severă pentru care agenţii antireumatici clasici cu acţiune lentă (inclusiv methotrexat) sunt ineficienţi sau inadecvaţi.

Monitorizarea atentă a pacienţilor este obligatorie.